

FDA-APPROVED BREAST CANCER TREATMENTS (Part 1 of 2)				
Generic	Brand	Strength	Form	Usual Dose
ALKYLATING AGENTS				
cyclophosphamide	—	25mg, 50mg	tabs	1–5mg/kg/day
	Cytosan injection	500mg, 1g, 2g	pwd for IV inj after reconstitution	40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly
thiotepa	—	15mg	pwd for IV, intravesical, or intra-cavitary admin after reconstitution	0.3–0.4mg/kg IV once every 1–4wks
ANTIBIOTICS (CYTOTOXIC)				
doxorubicin	—	10mg, 20mg, 50mg	pwd for IV inj after reconstitution	<i>Monotherapy:</i> 60–75mg/m ² every 21 days <i>Combination therapy:</i> 40–60mg/m ² every 21–28 days
		2mg/mL	soln for IV inj	
epirubicin	Ellence	2mg/mL	soln for IV infusion	100–120mg/m ² on Day 1 or divided equally given on Days 1 and 8 of each cycle
ANTIESTROGEN				
tamoxifen	—	10mg, 20mg	tabs	20–40mg/day
	Soltamox Oral Solution	10mg/5mL	oral soln	
toremifene	Fareston	60mg	tabs	60mg once daily
ANTIMETABOLITES				
capecitabine	Xeloda	150mg, 500mg	tabs	<i>Monotherapy:</i> 1250mg/m ² twice daily <i>Combination therapy:</i> Give with docetaxel 75mg/m ² IV infused over 1hr every 3wks
fluorouracil	—	50mg/mL	soln for IV inj	12mg/kg once daily for 4 successive days; max 800mg/day
gemcitabine	Gemzar	200mg, 1g	pwd for IV infusion after reconstitution	1250mg/m ² on Days 1 and 8 of each 21-day cycle
methotrexate	—	25mg/mL	soln for IV, IM, intra-arterial, or intrathecal admin after dilution	See drug monograph and manufacturer's full labeling
		1g	pwd for IV, IM, intra-arterial, or intrathecal admin after dilution	
	Trexall	5mg, 7.5mg, 10mg, 15mg	scored tabs	
ANTIMICROTUBULE AGENTS				
docetaxel	Taxotere	40mg/mL	soln for IV infusion after dilution	60–100mg/m ² once every 3wks
eribulin mesylate	Halaven	0.5mg/mL	soln for IV inj	1.4mg/m ² IV inj over 2–5min on Days 1 and 8 of each 21-day cycle
ixabepilone	Ixempra	15mg, 45mg	pwd for IV infusion after constitution and dilution	40mg/m ² once every 3wks
paclitaxel	Abraxane	100mg	IV infusion; inj susp after reconstitution	260mg/m ² every 3wks
	Taxol	6mg/mL	soln for IV infusion after dilution	175mg/m ² every 3wks
vinblastine	—	10mg	lyophilized pwd for IV inj or infusion after reconstitution	5.5–7.4mg/m ² once weekly (see full labeling)
		1mg/mL	soln for IV inj or infusion	
AROMATASE INHIBITOR				
anastrozole	Arimidex	1mg	tabs	1mg once daily
exemestane	Aromasin	25mg	tabs	25mg once daily
letrozole	Femara	2.5mg	tabs	2.5mg once daily
ESTROGEN				
conjugated estrogens	Premarin	0.3mg, 0.45mg, 0.625mg, 0.9mg, 1.25mg	tabs	10mg 3 times daily for at least 3mos
estradiol	Estrace	0.5mg, 1mg, 2mg	scored tabs	10mg 3 times daily for at least 3mos
ESTROGEN RECEPTOR ANTAGONIST				
fulvestrant	Faslodex	50mg/mL	soln for IM inj	Give by slow IM inj (over 1–2mins). <i>Monotherapy:</i> 500mg on Days 1, 15, 29, then once monthly thereafter. <i>Combination therapy:</i> give with palbociclib 125mg daily with food for 21 days, followed by 7 days off, or with abemaciclib 150mg twice daily; in pre/perimenopausal women: also treat with LHRH agonists.
(continued)				

FDA-APPROVED BREAST CANCER TREATMENTS (Part 2 of 2)

Generic	Brand	Strength	Form	Usual Dose
GnRH ANALOGUE				
goserelin	Zoladex	3.6mg	SC implant	One 3.6mg implant every 28 days
HER2-TARGETED ANTIBODY-DRUG CONJUGATE				
ado-trastuzumab emtansine	Kadcyla	100mg, 160mg	pwd for IV infusion after reconstitution	Give by IV infusion only over 90mins. 3.6mg/kg max every 3wks (21-day cycle) until disease progression or unacceptable toxicity. Subsequent infusions may be given over 30mins if previously tolerated.
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (HER2) INHIBITOR				
pertuzumab	Perjeta	420mg/14mL (30mg/mL)	soln for IV infusion	Initially 840mg IV over 60mins, followed every 3wks thereafter by a dose of 420mg IV over 30–60mins, in combination with trastuzumab. <i>MBC</i> : also give with docetaxel. <i>Neoadjuvant</i> : give every 3wks for 3–6 cycles as part of one of the treatment regimens for EBC (see full labeling). <i>Adjuvant</i> : give every 3wks for 1yr (up to 18 cycles) or until disease recurrence or unacceptable toxicity, whichever occurs first, as part of EBC regimen (see full labeling).
trastuzumab	Herceptin	440mg	lyophilized pwd for IV infusion after reconstitution and dilution	Initially 4mg/kg over 90mins, followed by 2mg/kg over 30mins weekly; administer until tumor progression. <i>Adjuvant treatment, combination therapy</i> : see full labeling.
KINASE INHIBITOR				
abemaciclib	Verzenio	50mg, 100mg, 150mg, 200mg	tabs	<i>Combination</i> : 150mg twice daily with fulvestrant (see full labeling); in pre/perimenopausal women: also treat with a gonadotropin-releasing hormone agonist. <i>Monotherapy</i> : 200mg twice daily. <i>Both</i> : continue until disease progression or unacceptable toxicity.
lapatinib	Tykerb	250mg	tabs	<i>HER2-positive (metastatic)</i> : 1250mg once daily on Days 1–21 continuously in combination with capecitabine 2000mg/m ² /day on Days 1–14 in a repeating 21 day cycle; continue until disease progression or unacceptable toxicity. <i>HR-positive, HER2-positive (metastatic)</i> : 1500mg once daily continuously in combination with letrozole 2.5mg once daily.
palbociclib	Ibrance	75mg, 100mg, 125mg	caps	125mg once daily for 21 days followed by 7 days off to complete a 28-day cycle, in combination with an aromatase inhibitor or with fulvestrant 500mg on Days 1, 15, 29, and once monthly thereafter. See full labeling.
ribociclib	Kisqali	200mg	tabs	600mg once daily for 21 days followed by 7 days off to complete 28-day cycle. Take with letrozole 2.5mg once daily, or other aromatase inhibitors, throughout the 28-day cycle. See full labeling.
mTOR KINASE INHIBITOR				
everolimus	Afinitor	2.5mg, 5mg, 7.5mg, 10mg	tabs	10mg once daily
POLY (ADP-RIBOSE) POLYMERASE INHIBITOR				
olaparib	Lynparza Tablets	100mg, 150mg	tabs	300mg twice daily until disease progression or unacceptable toxicity; max 600mg daily.
PROGESTIN				
megestrol acetate	—	20mg, 40mg	scored tabs	40mg 4 times daily
SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM)				
raloxifene	Evista	60mg	tabs	60mg once daily

NOTES

Key: MBC = metastatic breast cancer; EBC = early breast cancer

Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 2/2018)